Study of AZD4360 for Advanced Solid Tumours
This study is testing a drug called AZD4360 in people with advanced solid tumors, specifically gastric cancer, gastroesophageal junction cancer, biliary tract cancer, and pancreatic ductal adenocarcinoma. AZD4360 is an antibody-drug conjugate that targets Claudin 18.2 (CLDN18.2), a protein found on some cancer cells. The main goals are to understand the safety and side effects of AZD4360, as well as how your body handles the drug and if it shows any early signs of helping. You may be able to join if you are 18 or older, have a good performance status (meaning you can do most daily activities), and have a life expectancy of at least 12 weeks. The study plans to enroll 117 participants.
- Study design
- This is an interventional study, meaning participants will receive a specific treatment. It aims to enroll 117 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Safety will be measured through study completion, which is up to approximately 2 years.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Study for AZD4360 in Participants With Advanced Solid Tumours
At a glance
Conditions
Where it's being run
14 sites across 7 statesWho to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Incidence of participants with Dose-Limiting Toxicity (in dose escalation cohort), Adverse events (AEs) , Serious Adverse Events (SAEs) and AEs leading to discontinuation of AZD4360Through study completion, up to approximately 2 years
To investigate the safety and tolerability, and to determine the Maximum Tolerated Dose (MTD) and/or a Recommended Phase II Dose (R2PD) of AZD4360 in previously treated participants with advanced solid tumours, through the assessment of Dose Limiting Toxicities, Adverse Events and Severe Adverse Events.